Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...
Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...
Pharmaceutical company Eli Lilly (LLY) has been raking it in lately thanks to its two flagship products: Mounjaro and Zepbound. These two have ...
We recently compiled a list of the 12 Best Long-Term Stocks to Buy According to Ken Fisher. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...
Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic ...
Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
Hims & Hers Health Inc. is expanding beyond its successful foray into providing copycat weight-loss drugs with the ...